Beta Drugs Limited
₹2,130.00
+2.12%
Delayed · cached 15 min
Fair value analysis
BETA
Beta Drugs Limited
₹2,085.80
Close used for this calculation
₹977.70Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
34/100
Quality radar
Consensus fair value
₹977.70
Above FV▼ -53.1% against the close used
Model range ₹425.57 – ₹1,460.84
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₹425.57Fair value₹977.70Bull₹1,460.84
FairClose
52-week traded range
52W low ₹1,030.3052W high ₹2,668.30
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading above the consensus fair value
Beta Drugs Limited closed at ₹2,085.80, 113.3% above the consensus fair value of ₹977.70 drawn from 9 valuation models.
Financial DNA score 34/100 — Weak. P/E of 51.5x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₹812.22
-61.1%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
₹468.75
-77.5%
√(22.5 × EPS × BVPS)
EPS=40.92, BVPS=238.65 · outside Graham range (P/E 51.5, P/B 8.7) — asset-light, treat as a rough floor
Graham Formula
₹1,113.32
-46.6%
EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate
g=10.4%, FD=7%
P/E Fair Value
₹1,460.84
-30.0%
EPS × 35.7x (sector P/E)
EPS=40.92, Sector P/E=35.7x
Peter Lynch (PEG)
₹425.57
-79.6%
EPS × Growth% (PEG = 1 is fair)
EPS=40.92, g=10.4%
EV/EBITDA
₹1,123.79
-46.1%
(EBITDA × 15.2x − Net Debt) ÷ Shares
EBITDA=930M
Book Value (P/B)
₹763.68
-63.4%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=238.65, ROE=18.8%, g=6%, r=10%
Reverse DCF
₹2,085.80
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 19.8% | Historical: 10.4%
Margin of Safety
₹722.84
-65.3%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=963.78, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.